These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31290664)

  • 21. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
    Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HNF-1β in ovarian carcinomas with serous and clear cell change.
    DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
    Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.
    Kim O; Park EY; Klinkebiel DL; Pack SD; Shin YH; Abdullaev Z; Emerson RE; Coffey DM; Kwon SY; Creighton CJ; Kwon S; Chang EC; Chiang T; Yatsenko AN; Chien J; Cheon DJ; Yang-Hartwich Y; Nakshatri H; Nephew KP; Behringer RR; Fernández FM; Cho CH; Vanderhyden B; Drapkin R; Bast RC; Miller KD; Karpf AR; Kim J
    PLoS Genet; 2020 Jun; 16(6):e1008808. PubMed ID: 32497036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.
    Finkernagel F; Reinartz S; Schuldner M; Malz A; Jansen JM; Wagner U; Worzfeld T; Graumann J; von Strandmann EP; Müller R
    Theranostics; 2019; 9(22):6601-6617. PubMed ID: 31588238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole Reproductive System Non-Negative Matrix Factorization Mass Spectrometry Imaging of an Early-Stage Ovarian Cancer Mouse Model.
    Paine MR; Kim J; Bennett RV; Parry RM; Gaul DA; Wang MD; Matzuk MM; Fernández FM
    PLoS One; 2016; 11(5):e0154837. PubMed ID: 27159635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer.
    Cooper TT; Dieters-Castator DZ; Liu J; Siegers GM; Pink D; Veliz L; Lewis JD; Lagugné-Labarthet F; Fu Y; Steed H; Lajoie GA; Postovit LM
    J Ovarian Res; 2024 Jul; 17(1):149. PubMed ID: 39020428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening by Q Exactive liquid chromatography/tandem mass spectrometry identified Choline, 25-hydroxyvitamin D2, and SM(d18:0/16:1(9Z) (OH)) as biomarkers for high-grade serous ovarian cancer.
    Li J; Liu D; Cui M; Wei Z
    J Proteomics; 2024 May; 299():105154. PubMed ID: 38471622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer.
    Zhao Q; Laverdure JP; Lanoix J; Durette C; Côté C; Bonneil É; Laumont CM; Gendron P; Vincent K; Courcelles M; Lemieux S; Millar DG; Ohashi PS; Thibault P; Perreault C
    Cancer Immunol Res; 2020 Apr; 8(4):544-555. PubMed ID: 32047025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
    Wenk D; Khan S; Ignatchenko V; May T; Bernardini MQ; Kislinger T
    J Proteome Res; 2024 Feb; 23(2):749-759. PubMed ID: 38266179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
    Zhu YF; He LS; Zhang ZD; Huang QS
    Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA damage signaling and apoptosis in preinvasive tubal lesions of ovarian carcinoma.
    Chene G; Ouellet V; Rahimi K; Barres V; Caceres K; Meunier L; Cyr L; De Ladurantaye M; Provencher D; Mes Masson AM
    Int J Gynecol Cancer; 2015 Jun; 25(5):761-9. PubMed ID: 24987917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted Microchip Capillary Electrophoresis-Orbitrap Mass Spectrometry Metabolomics to Monitor Ovarian Cancer Progression.
    Sah S; Yun SR; Gaul DA; Botros A; Park EY; Kim O; Kim J; Fernández FM
    Metabolites; 2022 Jun; 12(6):. PubMed ID: 35736465
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Na K; Sung JY; Kim HS
    Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
    Niemi RJ; Braicu EI; Kulbe H; Koistinen KM; Sehouli J; Puistola U; Mäenpää JU; Hilvo M
    Br J Cancer; 2018 Oct; 119(7):847-854. PubMed ID: 30293997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
    Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
    [No Abstract]   [Full Text] [Related]  

  • 39. The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression.
    Quattrocchi L; Green AR; Martin S; Durrant L; Deen S
    Virchows Arch; 2011 Jul; 459(1):21-9. PubMed ID: 21509572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
    J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.